- Home
- WLK vs RPRX Comparison
WLK vs RPRX Comparison
Compare WLK & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLK
- RPRX
- Stock Information
- Founded
- WLK 1986
- RPRX 1996
- Country
- WLK United States
- RPRX United States
- Employees
- WLK N/A
- RPRX N/A
- Industry
- WLK Major Chemicals
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WLK Industrials
- RPRX Health Care
- Exchange
- WLK Nasdaq
- RPRX Nasdaq
- Market Cap
- WLK 13.8B
- RPRX 14.2B
- IPO Year
- WLK 2004
- RPRX 2020
- Fundamental
- Price
- WLK $91.85
- RPRX $32.60
- Analyst Decision
- WLK Buy
- RPRX Strong Buy
- Analyst Count
- WLK 13
- RPRX 4
- Target Price
- WLK $126.08
- RPRX $42.50
- AVG Volume (30 Days)
- WLK 939.2K
- RPRX 5.5M
- Earning Date
- WLK 05-02-2025
- RPRX 05-08-2025
- Dividend Yield
- WLK 2.28%
- RPRX 2.71%
- EPS Growth
- WLK 25.41
- RPRX N/A
- EPS
- WLK 4.64
- RPRX 1.91
- Revenue
- WLK $12,142,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- WLK $3.08
- RPRX $31.56
- Revenue Next Year
- WLK $6.05
- RPRX $5.94
- P/E Ratio
- WLK $19.80
- RPRX $17.05
- Revenue Growth
- WLK N/A
- RPRX N/A
- 52 Week Low
- WLK $81.41
- RPRX $24.05
- 52 Week High
- WLK $161.31
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- WLK 42.86
- RPRX 54.58
- Support Level
- WLK $88.78
- RPRX $32.02
- Resistance Level
- WLK $91.87
- RPRX $32.31
- Average True Range (ATR)
- WLK 5.18
- RPRX 0.97
- MACD
- WLK 0.27
- RPRX 0.12
- Stochastic Oscillator
- WLK 50.41
- RPRX 97.84
About WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.